# What Happens When You Stop a GLP-1: What the Withdrawal Trials Measured By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-15 | Updated: 2026-10-30 Canonical page: https://glpwatchdog.org/research/what-happens-when-you-stop-a-glp1 > Three trials took semaglutide or tirzepatide away from people who had lost weight on it, two of them by random assignment, and measured what came back: the weight, and the cardiometabolic gains with it. ## Key points - A year after semaglutide and its lifestyle program were withdrawn in the STEP 1 extension, participants had regained two-thirds of their prior weight loss, and cardiometabolic improvements had reverted toward baseline for most variables. - In SURMOUNT-4, weight changed by -5.5 percent over 52 weeks in those who stayed on tirzepatide against +14.0 percent in those switched to placebo; 89.5 percent versus 16.6 percent held at least 80 percent of their lead-in loss. - A post hoc analysis of that trial found blood pressure, glycated hemoglobin and non-HDL cholesterol rising on a gradient that tracked how much weight came back, not the fact of stopping. - Cost or an insurance problem was the recorded reason for 47.6 percent of people who stopped within a year in clinical practice; unsatisfactory weight loss accounted for 1.7 percent. Weight comes back. This is one of the few questions about GLP-1 drugs with a direct answer from trials, because three separate trials took people who had lost weight on semaglutide or tirzepatide and deliberately took the drug away, two of them by random assignment. A year after semaglutide and its lifestyle program were withdrawn, participants had regained two-thirds of what they lost.[1] In the tirzepatide withdrawal trial the placebo group put on 14.0 percent of body weight over the 52 weeks that followed.[3] What you do about it is a decision for you and your prescriber, and a careful reading of those results is less bleak than it first sounds. > **This article does not tell anyone to stop, to keep going, or how to do either.** There is no taper or schedule here, because that advice is not safe to give without knowing the person. If you are stopping, or being made to stop, tell the prescriber who has been managing you before it happens rather than after. ## The three trials that took the drug away on purpose Most drug trials measure what happens when you take something. These measured what happens when you stop, and they were designed that way from the start. Two used semaglutide, one used tirzepatide, and their designs differ in ways that matter when you read the numbers. *Withdrawal evidence in adults with overweight or obesity. STEP 4 and SURMOUNT-4 randomized who stopped; in the STEP 1 extension everyone stopped. Percentages are group means, not forecasts for any individual.* | Trial | Design | What happened after withdrawal | | --- | --- | --- | | **STEP 4** (semaglutide)[2] | 20-week run-in for everyone, then 803 who reached the maintenance dose split 2:1 to keep going or switch to placebo, both with lifestyle support. | Week 20 to week 68: -7.9% in the group that continued, +6.9% in the group switched to placebo. The gap is 14.8 percentage points. | | **STEP 1 extension** (semaglutide)[1] | Everything stopped at week 68, drug and lifestyle program alike, and 327 participants were followed for another year with no treatment at all. | Mean loss of 17.3% at week 68 shrank to 5.6% at week 120. Cardiometabolic gains drifted back toward where they started. | | **SURMOUNT-4** (tirzepatide)[3] | 36 weeks of open-label treatment first, then 670 people randomized to continue or switch to placebo for 52 weeks. | Week 36 to week 88: -5.5% continuing against +14.0% on placebo. Holding at least 80% of the lead-in loss: 89.5% against 16.6%. | All three show the weight returning. The STEP 1 extension needs a caveat, though: its analyses were exploratory, its extension covered a subset of sites rather than the whole trial, and the lifestyle program was withdrawn along with the drug, so it measures the removal of a whole program rather than of a molecule.[1] STEP 4 and SURMOUNT-4 kept lifestyle support running in both arms, which isolates the drug more cleanly, and they point the same way. The tirzepatide trial read week by week, with the label’s stopping and missed-dose rules, is in [stopping tirzepatide](https://glpwatchdog.org/research/stopping-tirzepatide-weight-regain). ## What comes back besides the number on the scale The scale is not the only thing that moves, and here the picture is less uniform. A post hoc analysis of SURMOUNT-4 sorted the people who came off tirzepatide by how much of their loss returned, then looked at what else moved.[4] Between week 36 and week 88, waist circumference grew by less than a centimeter on average in those who regained under a quarter of what they had lost, and by close to fifteen in those who regained three quarters or more. Systolic blood pressure, glycated hemoglobin and non-HDL cholesterol climbed on the same gradient, each one rising further in the bands that regained more.[4] Fasting insulin did not sort as tidily. Its largest rise landed in the second-heaviest regain band rather than the heaviest.[4] In the group whose weight barely moved, waist circumference, non-HDL cholesterol and fasting insulin at week 88 were not significantly different from where they had been at week 36.[4] > **Read that gradient carefully, in both directions.** It says the metabolic reversal tracked the weight regain rather than the act of stopping, which is more hopeful than “everything snaps back”. It does not say that anyone can choose which band they land in. It is a post hoc split of one trial's placebo arm, the groups were formed after the fact by outcome, and no one was randomized to regain a little. Across the wider literature the direction is the same. A 2025 systematic review pooled 18 randomized trials with at least twelve weeks of follow-up after treatment ended, covering 3,771 participants, and found weight and glycated hemoglobin both moving back in adults with obesity and in adults with type 2 diabetes, with the regain larger where follow-up ran past 26 weeks.[6] Its pooled figures need a caution. Heterogeneity across the included trials was extremely high on several of those estimates, so the average conceals a wide spread of individual trial results. The pattern is not limited to drugs: when [a stomach balloon came out on a date fixed in advance](https://glpwatchdog.org/research/the-day-the-balloon-comes-out), the group left without treatment began regaining. ## Appetite: what we can say, and what nobody published Readers describe hunger returning before the weight does, and the pharmacology makes that plausible: these drugs act at receptors involved in appetite and caloric intake, and that action ends when the drug is no longer there. What we could not find is a withdrawal trial reporting appetite or hunger on a validated scale as a published endpoint. So there is no number for it, and no week at which it happens. What these trials measured was body weight and cardiometabolic markers. The practical timeline after a last Ozempic or Wegovy dose is in [stopping Ozempic or Wegovy](https://glpwatchdog.org/research/stopping-semaglutide-weight-regain). If your appetite has changed since stopping and it is distressing you, describe it to a clinician, who can talk through the options. ## The drug leaves faster than the effect does People often assume the regain curve is the clearance curve, but the labels show the two are different. For semaglutide the label puts the elimination half-life at roughly a week, and says the drug will still be circulating some five to seven weeks after a last injectable 2.4 mg or 7.2 mg dose, or a 25 mg oral one.[9] Tirzepatide's half-life is approximately five to six days in people with overweight or obesity.[10] The same arithmetic for every GLP-1 is laid out in [how long GLP-1s stay in your system](https://glpwatchdog.org/research/how-long-glp1s-stay-in-your-system). So the molecule is gone within a couple of months, while the trials measured weight moving over a year. Whatever is happening after that first stretch is no longer the drug clearing. Our article on [how long GLP-1 side effects last](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last) covers the pharmacokinetics in more detail, including what the long tail means for symptoms that persist after a last dose. ## If you have type 2 diabetes, this is a different conversation Ozempic and Mounjaro are indicated for diabetes rather than for weight. Both are approved to control blood sugar in type 2 diabetes, alongside diet and exercise; Mounjaro’s approval extends to children from age 10. Each label now carries a second, cardiac use as well: in people with diabetes and raised heart risk, fewer heart attacks, strokes and deaths from heart disease. Mounjaro gained it in August 2026.[11][12] Stopping one of them removes a glucose-lowering medicine from a regimen built around it, which is a different kind of event from regaining weight. The evidence here is thinner than the weight evidence. The three withdrawal trials above all excluded diabetes. What exists is the meta-analysis subgroup, where glycated hemoglobin rose after discontinuation in people with type 2 diabetes and rose by more than it did in people with obesity alone, again with high heterogeneity behind the pooled estimate.[6] Alongside it sits one long-term signal that runs the other way: in the three-year SURMOUNT-1 report, participants with obesity and [prediabetes](https://glpwatchdog.org/research/glp1-for-prediabetes) who then spent seventeen weeks off treatment were still far less likely to have received a diabetes diagnosis than the placebo group.[5] > **An unannounced stop is a monitoring problem as well as a weight one.** If a GLP-1 is part of how your blood sugar is being managed, the person managing it needs to know before the supply ends, because other medicines in the regimen may be sized around it. Cost or a program closing is a legitimate reason to stop, and it is still a reason to call first. ## Why people stop The trials answer what happens. They do not answer why anyone is in this position, and the real-world data on that is unflattering to the market rather than to the patients. Researchers reviewed the records of 288 adults who had started injectable semaglutide or tirzepatide for obesity and stopped inside the first year, and read the reason recorded for each.[7] - **Cost or an insurance problem: 47.6 percent.** Nearly half, ahead of every other reason.[7] - **Could not tolerate the side effects: 14.6 percent.**[7] - **Could not fill the prescription because of a shortage: 11.8 percent.**[7] - **Switched to a compounded medication: 2.4 percent.**[7] - **Unsatisfactory weight loss: 1.7 percent.** The reason people assume dominates this list is close to the bottom of it.[7] That matters for how the results above should be read. A separate cohort of 7,881 patients from the same health system found one-year weight reduction of 3.6 percent among those who stopped early, 6.8 percent among those who stopped later in the year, and 11.9 percent among those who did not stop, with most patients on low maintenance dosages throughout.[8] The authors' own explanation for why their average fell short of the trial results was discontinuation and dosing rather than anything about the drug.[8] If cost is what is pushing this decision, say that to your prescriber before you stop rather than after, and check the dated figures on our [price tracker](https://glpwatchdog.org/price-tracker) against whatever you are being quoted. Where a compounded program is the thing ending, we walk through the remaining routes in [what to do when a compounded GLP-1 program ends](https://glpwatchdog.org/research/compounded-glp1-going-away-what-to-do), and the cash routes for the approved products in [what semaglutide costs without insurance](https://glpwatchdog.org/research/semaglutide-cost-without-insurance). If you do stop, the timing of the request matters more than most sellers make obvious. [Heros Health](https://glpwatchdog.org/reviews/heros-health) asks for notice at least 48 hours before the renewal date and keeps access running to the end of the paid period. At [CaliberRx](https://glpwatchdog.org/reviews/caliberrx) a cancellation sent less than 48 hours before renewal may not stop that charge, and refunds are not prorated. [TeleDocs360](https://glpwatchdog.org/reviews/teledocs360) needs the request before the next billing date and before a medication order is submitted. [SkinnyRx](https://glpwatchdog.org/reviews/skinnyrx) asks for cancellation at least 5 days before the renewal date, and its terms allow renewals to be charged up to 5 days early. Some make stopping simpler. [Happy Care Meds](https://glpwatchdog.org/reviews/happy-care-meds) sells each order as a single purchase that does not renew, so there is nothing to cancel. [Green Cap Health](https://glpwatchdog.org/reviews/green-cap-health) takes cancellations in its portal, by email or by phone, though its subscriptions renew automatically and its 3- and 6-month programs carry a commitment. [9amHealth](https://glpwatchdog.org/reviews/9am-health) accepts them by email, phone, text or its in-app messenger. Medication already dispensed is almost never refundable. [ZYP Medical](https://glpwatchdog.org/reviews/zyp-medical) calls all sales final but returns part of a prepaid plan if it is canceled before a later vial ships. [BioGlow Health](https://glpwatchdog.org/reviews/bioglow-health) refunds orders that were not fulfilled or were canceled, and nothing once the pharmacy dispenses; its homepage says you can cancel anytime, but its terms do not say how. [Zealthy](https://glpwatchdog.org/reviews/zealthy) lets you cancel anytime, yet treats medication, consultation and membership charges alike as non-refundable, so money already paid stays paid. ## The framing that fits the evidence None of this is a story about willpower, and the trial authors did not treat it as one. The STEP 1 extension investigators put their own conclusion in the paper's abstract. > Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health. > > — Wilding et al., STEP 1 trial extension, Diabetes Obes Metab 2022 Read plainly, that is a statement about a class of medicine rather than about the people taking it. Blood pressure returns when an antihypertensive stops, and nobody calls that a relapse. The withdrawal trials establish that these drugs work while they are being taken and that the condition they treat is still there underneath. That bears on how treatment should be planned and paid for, not on anyone's discipline. It also means stopping is a real decision, with a trade-off on both sides that no article can settle for you. The multi-year safety record that belongs on the other side of that scale is in [tirzepatide long-term side effects](https://glpwatchdog.org/research/tirzepatide-long-term-side-effects). The person who can weigh both against your own history is your prescriber. ## Frequently asked questions ### What happens when you stop taking semaglutide? Weight returns for most people, and the trials measured it directly. In the STEP 1 extension, where both the drug and the lifestyle program were withdrawn at week 68, participants had regained about two-thirds of what they lost when they were reassessed a year later. In STEP 4, where lifestyle support continued in both arms, the people switched to placebo gained 6.9 percent of body weight over 48 weeks while those who stayed on treatment lost a further 7.9 percent. Cardiometabolic improvements moved back toward baseline as well. Those are group averages from trials, not a prediction for one person. ### What happens when you stop taking tirzepatide? The same pattern, from a trial built to test it. SURMOUNT-4 gave everyone tirzepatide for 36 weeks, then randomized 670 people to continue or to switch to placebo for 52 weeks. The placebo group gained 14.0 percent of body weight over that year while the continuing group lost another 5.5 percent, and 89.5 percent of those who continued held at least 80 percent of their initial loss against 16.6 percent of those who stopped. ### How quickly does weight come back after stopping? The trials report the position at the end of a follow-up year rather than a week-by-week curve, so the most the data can say is that it accrues over months rather than arriving at once. A 2025 systematic review of 18 randomized trials found the regain larger in the studies whose follow-up ran beyond 26 weeks than in the shorter ones, which points the same way. Individual results in those trials varied enormously, and the review's own statistics show that spread. ### How long does the drug stay in my system after my last dose? The labels answer this. For semaglutide the elimination half-life is given as roughly a week, and the Wegovy prescribing information says the drug is still circulating some five to seven weeks past a last injectable 2.4 mg or 7.2 mg dose, or a 25 mg oral one. Tirzepatide's half-life is approximately five to six days in people with overweight or obesity. The drug is gone long before the weight trajectory in the trials had finished moving, so what happens after the first couple of months is not the medicine clearing. ### Does blood sugar control come back too if I have type 2 diabetes? Glycated hemoglobin rose after discontinuation in the type 2 diabetes subgroup of the 2025 meta-analysis, and rose by more than it did in participants with obesity alone. The three big withdrawal trials all excluded diabetes, though, so that finding is a pooled subgroup rather than a dedicated trial, and the heterogeneity behind it is high. Either way, Ozempic and Mounjaro are both approved for blood-sugar control alongside diet and exercise, so stopping removes a glucose-lowering medicine from a regimen that may have been built around it. That is a reason to tell whoever manages your diabetes before the supply runs out. ### Is regaining the weight a sign the drug failed, or that I did? Neither, on the evidence. The investigators on the STEP 1 extension concluded that their findings confirmed the chronicity of obesity and suggested ongoing treatment is needed to maintain the improvements. A medicine that works while it is taken and stops working when it is not is behaving the way chronic-disease medicines behave. What it does mean is that the cost and the supply questions are clinical questions rather than administrative ones, because they determine whether treatment continues. ### Should I taper rather than stop suddenly? We will not answer that, and you should be wary of any page that does without knowing you. It is a dosing decision, it depends on which molecule you are on, why you are stopping, what else you take and what your prescriber is watching, and none of that is on this page. What we can tell you is that the question is worth raising explicitly rather than assuming, and that cost or a program closing is a legitimate thing to say out loud when you raise it. ## References 1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564. 2022. PMID: 35441470. https://pubmed.ncbi.nlm.nih.gov/35441470/ 2. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021;325(14):1414-1425. 2021. PMID: 33755728. https://pubmed.ncbi.nlm.nih.gov/33755728/ 3. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. 2024. PMID: 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/ 4. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med 2026;186(2):157-167. 2026. PMID: 41284285. https://pubmed.ncbi.nlm.nih.gov/41284285/ 5. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med 2025;392(10):958-971. 2025. PMID: 39536238. https://pubmed.ncbi.nlm.nih.gov/39536238/ 6. Tzang CC, Wu PH, Luo CA, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine 2025;90:103680. 2025. PMID: 41399474. https://pubmed.ncbi.nlm.nih.gov/41399474/ 7. Gasoyan H, Butsch WS, Casacchia NJ, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity (Silver Spring) 2025;33(12):2296-2303. 2025. PMID: 41039650. https://pubmed.ncbi.nlm.nih.gov/41039650/ 8. Gasoyan H, Butsch WS, Schulte R, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity (Silver Spring) 2025;33(9):1657-1667. 2025. PMID: 40491239. https://pubmed.ncbi.nlm.nih.gov/40491239/ 9. Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection and tablets — prescribing information, section 12.3 Pharmacokinetics. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 10. Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, sections 1 and 12.3. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 11. Novo Nordisk Pharmaceutical Industries, LP OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, section 1 Indications and Usage. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 12. Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information, section 1 Indications and Usage. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 --- Cite as: GLP Watchdog, Ruth Calder, "What Happens When You Stop a GLP-1: What the Withdrawal Trials Measured", published 2026-08-15, updated 2026-10-30. https://glpwatchdog.org/research/what-happens-when-you-stop-a-glp1 Canonical HTML page: https://glpwatchdog.org/research/what-happens-when-you-stop-a-glp1 Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.